Research analyst, medium-term horizon, biotech, small-cap

Depomed Shares Offer 50% Upside Over The Next Six Months

On August 6, 2014, Depomed, Inc. (NASDAQ:DEPO) reported financial results for the second quarter ended June 30, 2014. Total revenues in the quarter were $67.7 million, up 126% from the second quarter 2013 and handily beating Street expectations of only $38.0 million. However, we note almost all the upside came from greater than expected recognition of non-cash royalties associated with the PDL BioPharma transaction in October 2013. Revenues from product sales totaled $28.2 million, up 100% year-over-year and dead-on with our forecast. Licensing and milestone revenues of $5.8 million were up 658% from the second quarter 2014 and generally in-line with our thinking. The table below provides greater detail on each line item:

(click to enlarge)

For the

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details